Zydus Wins Appeal in Shire’s Patent Case Over Generic Lialda for UC

Zydus Wins Appeal in Shire’s Patent Case Over Generic Lialda for UC
Zydus Pharmaceuticals won a patent battle over Shire’s ulcerative colitis drug Lialda (mesalamine), with the U.S. Court of Appeals for the Federal Circuit ruling that Zydus' proposed generic version of Lialda does not infringe upon Shire's patent covering the drug. “We welcome this decision, which is a positive step and will help us further our mission of making available high-quality, affordable generic products to our customers and their patients,” Pankaj R. Patel, chairman and managing director at Zydus Cadila, said in a press release. Mesalam
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *